Publications and Presentations

Check out our publications and poster presentations.

November 2015

Identification of Biomarkers and Combination Agents for the Glutaminase Inhibitor CB-839 for the Treatment of Cancer

GTC Biotech November – 2015

November 2015

Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors Targeting glutamine metabolism in colorectal cancers with PIK3CA mutations

NCI AACR EORTC – 2015

November 2015

CB-1158 Inhibits the Immuno-Oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response

NCI AACR EORTC – 2015

June 2015

Phase 1 Study: Safety and Tolerability of Increasing Doses of CB-839, An Orally-Administered Small Molecule Inhibitor of Glutaminase, in Acute Leukemia

European Hematology Association

May 2015

Safety and Tolerability of Increasing Doses of CB-839, a First-in-class, Orally Administered Small Molecule Inhibitor of Glutaminase, in Solid Tumors

American Society of Clinical Oncology – May 2015

Our Pipeline

We are focused on solid tumors for
which new treatments are urgently needed.

View Our Pipeline